Supportive Care | Specialty

The OncLive Supportive Care condition center page is a comprehensive resource for clinical news and expert insights on supportive care and management of patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, best practices, and ongoing research as it relates to supportive care for patients with cancer.

Risk Stratification in Renal Cell Carcinoma

June 25th 2014

Prognostic Factors and Treatment Selection in RCC

June 25th 2014

High-Risk Renal Cell Carcinoma Treatment

June 25th 2014

Introduction and Frontline Treatment of RCC

June 25th 2014

Survey Finds Wide Gaps in Cancer Care Communications

June 18th 2014

A significant proportion of oncology patients and caregivers feel they are not getting the information they want from their cancer care team, and nearly 1 in 4 are dissatisfied with the care provided during their treatment journey

Conclusion: Improving Outcomes in Melanoma

June 17th 2014

Surgery Following Systemic Therapy in Melanoma

June 17th 2014

Nivolumab Plus Ipilimumab in Advanced Melanoma

June 17th 2014

Immunotherapy Combinations in Advanced Melanoma

June 17th 2014

Novel Therapies in Metastatic Melanoma

June 17th 2014

Strategies for the Detection of Recurrent Melanoma

June 17th 2014

Ipilimumab Side Effect Management in Melanoma

June 17th 2014

Adjuvant Treatment Selection in High-Risk Melanoma

June 17th 2014

Adjuvant Therapy for Stage III Melanoma

June 17th 2014

Role of Adjuvant Radiation Therapy in Melanoma

June 17th 2014

Molecular Testing in Resectable Melanoma

June 17th 2014

Lymph Node Management in Melanoma

June 17th 2014

Imaging and SLN Biopsy for Patients With Melanoma

June 17th 2014

Introduction: Surgical Excision of Melanoma

June 17th 2014

Dr. Sequist Discusses Adverse Events Associated With CO-1686

June 16th 2014

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer.